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Abstract: Disrupted systemic copper (Cu) homeostasis underlies neurodegenerative diseases with
early symptoms including olfactory dysfunction. This study investigated the impact of Cu dyshomeostasis on olfactory function, adult neurogenesis, and neurochemical balance. Models of Cu deficiency
(CuD) and Cu overload (CuO) were established by feeding adult rats with Cu-restricted diets plus ip.
injection of a Cu chelator (ammonium tetrathiomolybdate) and excess Cu, respectively. CuD reduced
Cu levels in the olfactory bulb (OB), subventricular zone (SVZ), rostral migratory stream (RMS), and
striatum, while CuO increased Cu levels in these areas. The buried pellet test revealed both CuD
and CuO prolonged the latency to uncover food. CuD increased neural proliferation and stem cells
in the SVZ and newly differentiated neurons in the OB, whereas CuO caused opposite alterations,
suggesting a “switch”-type function of Cu in regulating adult neurogenesis. CuO increased GABA
in the OB, while both CuD and CuO reduced DOPAC, HVA, 5-HT and the DA turnover rate in
olfactory-associated brain regions. Altered mRNA expression of Cu transport and storage proteins
in tested brain areas were observed under both conditions. Together, results support an association
between systemic Cu dyshomeostasis and olfactory dysfunction. Specifically, altered adult neurogenesis along the SVZ-RMS-OB pathway and neurochemical imbalance could be the factors that may
contribute to olfactory dysfunction.
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1. Introduction
Copper (Cu) is an essential element for human health serving as an indispensable cofactor for numerous enzymes and proteins that are widely involved in a number of diverse
biochemical reactions [1–4]. In the central nervous system (CNS), Cu-containing enzymes
such as cytochrome C oxidase, superoxide dismutase, dopamine-β-monooxygenase, and
tyrosinase, play pivotal roles in various biological processes, such as energy metabolism,
iron metabolism, anti-oxidative defense, and synthesis of neurotransmitters and neuropeptides, among others [5–8]. Nevertheless, by actively interacting with oxygen, excessive free
Cu ions can initiate a cascade of reactions leading to the generation of highly damaging
hydroxyl radicals. Thus, a dyshomeostasis of Cu, in either the form of Cu deficiency (CuD)
or Cu overload (CuO), is deemed disruptive to normal brain function.
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Imbalanced Cu homeostasis has been well characterized in two inherited neurodegenerative disorders, i.e., Menkes disease and Wilson’s disease. In Menkes disease, Cu
deficiency occurs due to ATP7A mutations while in Wilson’s disease, a genetic defect in
ATP7B causes excessive Cu accumulation in the liver and brain [9,10]. A large body of
evidence has also implicated a disrupted Cu homeostasis in pathogeneses of neurodegenerative disorders, e.g., Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic
lateral sclerosis, prion disease, and Huntington’s disease [11–15]. Our own human studies
on manganese exposure-associated Parkinsonian disorder reveal that Cu levels are significantly higher in blood, serum, and saliva samples from manganese-exposed smelters
and welders compared to control workers [16–18]. Moreover, studies by our laboratory
and others on manganese-poisoned animal models (non-human primates and rodents)
demonstrate a significant increase of Cu in brain regions including caudate putamen, striatum, hippocampus, and choroid plexus [19–22]. Thus, Cu dyshomeostasis unequivocally
underlies neurodegenerative diseases and disorders.
By using synchrotron X-ray fluorescent microscopy, we have reported an extraordinarily high Cu level in the subventricular zone (SVZ) of the rat brain [23]. Data by atomic
absorption spectrophotometry further confirm significantly elevated Cu levels in the SVZ
and olfactory bulb (OB) compared to other brain regions [19,24]. Importantly, the SVZ
is an active proliferative niche in the adult brain. Limited data have suggested a role of
Cu in regulating embryonic stem cell differentiation [25–27]. Given the higher levels of
proliferation, migration, and differentiation occurring in the SVZ, it seems likely that the
high Cu environment may be required to maintain normal energy metabolism and/or other
biochemical reactions deemed to be essential to adult neurogenesis. However, there is a
clear lack of knowledge on the role and mechanisms of Cu in regulating adult neurogenesis
in the SVZ and OB.
During adult neurogenesis, new neurons are generated from two proliferative niches
in adult brain, i.e., the SVZ in the lateral ventricles and the subgranular zone (SGZ) in the
hippocampus. The SVZ is rich in neural stem/progenitor cells (NSPCs) and functions as
the origin of adult neurogenesis [28,29]. The SVZ possesses 4 cell types: (i) ependymal
cells facing the cerebrospinal fluid (CSF), which is secreted and regulated by the choroid
plexus in brain ventricles, (ii) β-tubulin or Doublecortin (DCX)-positive Type A migratory
neuroblasts, (iii) glial fibrillary acid protein (GFAP)-positive Type B astrocytic stem cells,
and (iv) Nestin-positive Type C transit-amplifying cells. Newly generated NSPCs in the
SVZ can migrate alongside the rostral migratory stream (RMS) to reach the OB [29,30]. On
this SVZ-RMS-OB pathway, the proliferating cells further differentiate in adjacent brain
regions to supply renewed neurons and to compensate for the loss of neurons in order to
maintain normal brain function [28,31].
Loss of neurons in selective brain regions is a pathological characteristic of numerous
neurodegenerative diseases including PD. Olfactory impairments, such as deficits in odor
identification, detection, and discrimination, are found in patients with PD and AD [32–36].
Olfactory deficits can trigger aberrant adult neurogenesis in the SVZ-RMS-OB system.
Previous studies in zebrafish have shown that Cu is capable of inducing olfactory dysfunction, abnormal neurogenesis, and dysfunctional locomotor behavior [4]. Clinical evidence
also suggests an olfactory dysregulation in patients with Cu-homeostasis dysfunctions
in Wilson’s disease [37,38]. Thus, it has become necessary to investigate the role of Cu in
regulating adult neurogenesis in the SVZ, which ultimately affects olfactory function.
Maintaining a balanced cellular Cu homeostasis requires close coordinations among
a group of Cu regulatory proteins [6,39]. These include Cu transporter-1 (CTR1) and
divalent metal transporter-1 (DMT1) which function to regulate Cu uptake by the cell
membrane [40]. Further, there are various isoforms of metallothioneins regulating intracellular Cu storage [6]. These Cu regulatory proteins exist in the mammalian brain with a
particular abundance in the brain capillary endothelial cells constituting the blood-brain
barrier and in the choroid plexus epithelial cells forming the blood-CSF barrier [6,39,41–43].
Our recent data has confirmed the presence of these regulatory proteins in the SVZ [19].
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Conceivably, disruption of Cu systemic homeostasis would adversely affect the expression
of these Cu regulatory proteins in the Cu-rich SVZ, which would in turn affect normal
olfactory function.
The current study was designed to investigate whether alteration of systemic Cu
levels, resulting from either Cu deficiency (CuD) or Cu overload (CuO) conditions, has any
impact on olfactory function in adult rats through the modulation of adult neurogenesis in
the Cu-rich SVZ and OB, and to determine the ensuring alteration of neurochemical balance
within the OB. We first established and verified animal models of CuD and CuO, followed
by examining alterations in olfactory function. Further, we investigated the mechanism by
which CuD or CuO interrupted adult neurogenesis and neurochemical balance in brain
regions critical to the olfactory function.
2. Material and Methods
2.1. Materials
Chemical reagents were purchased from the following sources: mouse monoclonal
anti-BrdU antibody from Santa Cruz Biotechnology (Dallas, TX, USA), ProLong Gold antifade reagent, Alexa Fluor 488 goat anti-rabbit IgG (H+L) antibody (Catalog No. A11008)
and Alexa Fluor 555 goat anti-mouse IgG (H+L) antibody (Catalog No. A21424) from Life
Technologies (Carlsbad, CA, USA); anti-doublecortin (DCX) (Catalog No. ab18723) and antiNeuN (Catalog No. ab177487) antibodies, and chicken polyclonal anti-glial fibrillary acidic
protein (GFAP) antibodies from Abcam (Cambridge, MA, USA); anti-tyrosine hydroxylase
sheep polyclonal antibody (Catalog No. AB1542) from Millipore (Burlington, MA, USA);
anti-GAD67 mouse monoclonal antibody (Catalog No. ab26116) from Abcam (Branford, CT,
USA); paraformaldehyde (PFA) from ACROS Organics (Morris Plains, NJ, USA); bovine
serum albumin (BSA) from AMRESCO (Solon, OH, USA); and normal goat serum and
normal donkey serum from Jackson Immuno Research Labs (West Grove, PA, USA). All
reagents were of analytical grade, HPLC grade, or the best available pharmaceutical grade.
2.2. Animals and Treatment
Male Sprague–Dawley rats were purchased from Taconic Biosciences (Hudson, NY,
USA). At the time of use, the rats were 10-weeks old weighing 220–250 g. Upon arrival,
rats were housed in a temperature-controlled, 12/12-h light/dark cycle room and allowed
to acclimate for one week prior to experimentation. Rats were provided with deionized
water and designated pellet (See details in systemic Cu-deficiency/overload treatments) ad
libitum. The study was conducted in compliance with standard animal use practices and approved by the Animal Care and Use Committee of Purdue University (Protocol#1112000526
approved on 17 May 2019).
The methods to create systemic Cu deficiency (CuD) and Cu overload (CuO) rat
models have been extensively published in literature [44–52]. In addition to Cu-controlled
diet, the CuD and CuO models require ip. injections of a Cu chelator or Cu supplement,
respectively. Thus, we modified existing approaches and designed the protocol as illustrated in Figure 1A. Briefly, after a 1-week acclimation period, rats were randomly assigned
to control, CuD, or CuO groups. CuD rats had free access to a modified AIN-93G purified CuD diet containing 0.3 ppm Cu (Teklad Diets from Envigo Corp, Indianapolis, IN,
USA); CuD rats also received ip. injections of 10 mg/kg of the Cu chelator ammonium
tetrathiomolybdate (TTM) once daily for 7 days a week. CuO rats had free access to a
normal AIN-93G purified CuO diet containing 6 ppm Cu (Teklad Diets from Envigo Corp,
Indianapolis, IN, USA); these rats also received ip. injections of 3 mg Cu/kg as CuCl2 once
daily for 7 days a week. Control rats had free access to the normal AIN-93G purified diet
and received daily ip. injections of saline. All treatments lasted for 2 consecutive weeks.
Cu concentrations in serum, plasma, and cerebrospinal fluid (CSF) of treated animals were
determined by atomic absorption spectrophotometry (AAS) to verify the effectiveness of
CuD and CuO treatments.
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Olfactory function was evaluated via the buried pellet test which is based on the time
time taken to uncover a buried food pellet hidden under the bedding, as described in
taken to uncover a buried food pellet hidden under the bedding, as described in literature
literature [53–55]. In brief, 24 h after the last treatment, rats were placed in a clean cage
[53–55]. In brief, 24 hrs after the last treatment, rats were placed in a clean cage (48-cm
(48-cm length × 25-cm width × 20-cm height) and provided with several pieces of the
length × 25-cm width × 20-cm height) and provided with several pieces of the pellets
pellets (mini marshmallows) for three consecutive days with food restriction to 85–90% of
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room for 1 h with no water bottle and feeder bin but with a filter top lid.
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2.4. Brain Tissue Collection
All animals were anesthetized using ketamine/xylazine (75:10 mg/kg, 1 mg/kg
ip.). Blood and CSF samples were collected, followed by brain dissection. Brains were
removed from the skull, one hemisphere was fixed by 4% paraformaldehyde (PFA) in
phosphate-buffered saline (PBS) for 7 days and subjected to immunohistochemistry studies.
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The other hemisphere was dissected to harvest brain regions including the olfactory
bulb (OB), lateral olfactory tract (LOT) also known as anterior rostral migratory stream
(aRMS), subventricular zone (SVZ), choroid plexus (CP), striatum (STR), hippocampus
(HP), frontal cortex (FC), and cerebellum (CB). The harvested brain samples were stored at
−80 ◦ C freezer for AAS, qPCR and HPLC analyses.
2.5. Determination of Cu Concentration by Atomic Absorption Spectroscopy (AAS)
Prior to AAS quantification of Cu levels, brain samples were digested with concentrated ultrapure HNO3 in a MARSXpress microwave-accelerated reaction system. Samples
of SVZ, choroid plexus, CSF, and plasma were digested overnight with HNO3 in the oven at
55 ◦ C. An Agilent Technologies 200 Series SpectrAA with a GTA 120 graphite tube atomizer
was used to quantify Cu concentrations. Digested samples were diluted by 50, 500, or
1000 times with 0.1% (v/v) HNO3 in order to maintain a reading within the concentration
range of the Cu standard curve. The Copper AAS Standard (1000 mg/L in 5% nitric acid)
was purchased from Agilent Technologies (Part #5190-8279). The calibration standard
range for Cu was 0–25 µg/L and the detection limit for Cu was 0.9 ng/mL of the assay
solution. Intra-day precision of the method for Cu was 1.6% and inter-day precision was
3.7% [19,24,41,56].
2.6. Immunohistochemistry (IHC) Staining
Following the fixation with 4% PFA for 7 days, brain hemispheres were dehydrated
in 30% sucrose for another 7 days. Serial 30-µm thick coronal or sagittal sections were
cut using a microtome and stored in cryoprotectant solution at −20 ◦ C. Specifically, for
coronal and sagittal sectioning, the brains were sectioned roughly from Bregma 2.0 mm
to −6.0 mm (coronal) and Lateral 0.2 mm to 4.0 mm/hemisphere (sagittal) according to
the rat brain atlas in order to cover the entire distance of the SVZ, which yielded about
250–270 sections/brain (coronal) and 125–135 sections/hemisphere (sagittal). All of the
coronal sections were placed in a twelve-well plate in serial order, and all of the sagittal
sections collected from one hemisphere were placed in 6 wells of the twelve-well plate
in serial order. Each well contained about 18–22 sections for both coronal and sagittal
sections, which accounted for 1/12 of the total brain sections. The 18–22 sections within the
same well and with the same well number order across all animals were then processed for
immunohistochemistry (IHC) staining.
Every twelfth section (360 µm interval), covering the distance of the lateral ventricle
and OB, was processed for IHC analysis. Sections were incubated with various primary
antibodies against GAD67 (1:5000), tyrosine hydroxylase (TH) (1:500), anti-doublecortin
(DCX) (1:1000), Nestin (1:500), or NeuN (1:2000) overnight at 4 ◦ C. Free-floating sections
were washed with PBS (3 × 10 min/wash), incubated in 2N HCl for 2 h at room temperature,
and then blocked in 0.1 M borate buffer for 15 min (pH 8.4). After 3 washes with PBS
(10 min/wash), sections were incubated in blocking solution (0.3% Triton X-100, 1% BSA,
and 5% normal goat serum in PBS) for 1.5 hr at room temperature, followed by overnight
incubation with mouse anti-BrdU (1:500) at 4 ◦ C. The sections were washed with PBS
(3 × 10 min) and incubated with Alexa Fluor 555 goat anti-mouse IgG (H+L) antibody
(1:500) for 2 h at room temperature. For imaging, sections were further incubated with
DAPI (40 ,6-diamidino-2-phenylindole) in secondary antibody solution for 15 min at room
temperature. All sections were then rinsed with PBS (3 × 10 min) and mounted using
Fluorescent Mount G.
2.7. Confocal Imaging and Cell Counting
After IHC processing, brain sections were examined using a Nikon TE2000-U inverted
microscope equipped with a Nikon A1 confocal system from Nikon Instruments Inc.
(Melville, NY, USA). Images were taken using the software NIS Elements AR (v4.20). All
images were assembled and labeled in Photoshop CC. For cell counting, all sections were
analyzed with appropriate filter or laser combinations under an objective lens of 20×/0.75
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(DIC N2, ∞0.17 WD). Large image plus Z-Stack scanning was employed to confine the
entire SVZ from coronal.
IHC was performed simultaneously on sections from different groups to detect the
target cells. Series of every twelfth section (30 µm thickness, 360 µm apart) through each
lateral ventricle were processed. The cell density was determined through a blinded
quantitative histological analysis. A profile count method was used; every single BrdU(+)
cell including partial of BrdU(+) nuclei at the border of section, or BrdU and DAPI doublelabeled cells in the different sub-region of HDG in the multiplanes throughout the entire
30 µm section, were counted under the fluorescent or confocal microscope using the large
Z-stacking images through a whole series of sections. Those BrdU/DAPI labeled cells
were considered the target cells for cell counting. The total number of quantified cells was
justified by correction [57,58]. The total number of BrdU/DAPI labeled cells were then
calculated by the following equation:
Total cell number = the sum of actual cell counting number × 12 and expressed as
total number/target region/brain (n = 3 or 4 brains for each group).
2.8. High-Performance Liquid Chromatography (HPLC)
Neurochemical analysis was performed similarly to described in previous studies [59,60]. Briefly, frozen brain samples were sonicated in 0.5 mL of 0.4 N perchloric
acid (HClO4 ) on ice. Samples were then centrifuged at 16,400× g for 35 min at 4 ◦ C. The
supernatant was transferred to a 0.22 mm Spin-X tube with nylon filter (Corning, Corning,
NY, USA) and centrifuged at 1000× g for 15 min at 4 ◦ C. Samples were then stored at
−80 ◦ C until HPLC analysis.
The HPLC system consisted of a Dionex Ultimate 3000 Model ISO-31000BM pump, a
model WPS-3000TBSL autosampler, Coulochem III electrochemical detector and an ESA
Coulochem data station (ThermoScientific, Waltham, MA, USA) was used to measure neurotransmitter levels including GABA, glutamate, dopamine (DA), 3,4-Dihydroxyphenylacetic
acid (DOPAC), homovanillic acid (HVA), serotonin (5-HT), 5-hydroxyindoleacetic acid
(5-HIAA), and norepinephrine (NE) in the brain tissues of SVZ, STR, HP, and OB.
Neurochemicals were separated on a Waters XBridge reverse-phase G18 column
(150 × 3.0 mm, 3.5 µm particle size) (Water Corp, Milford, MA, USA). For monoamine
separation, the mobile phase was: 80 mM NaH2 PO4 , 10% methanol, 2 mM octanesulfonic
acid, 0.025 mM ethylenediaminetetraacetic acid and 0.2 mM trimethylamine, at pH 2.4.
Monoamines were detected by analytical cell set at E1 = −150 mV and E2 = +350 mV.
For quantification of GABA and glutamate, the mobile phase was 0.1 M Na2 HPO4 , 22%
methanol and 4% acetonitrile, at pH 6.75. Quantification of amino acid neurotransmitters
was accomplished through derivatization. The samples were mixed with a derivatization
agent containing 0.M o-phthaladehyde (OPA), 0.05% 2-mercaptoethanol, 10% methanol
in OPA diluent, prior to separation. Neurotransmitters in the sample were detected by
analytical cell set at E1 = −150 mV and E2 = +550 mV. Levels of neurotransmitters tested
here were calculated using area under the curve by comparison with standard curve. Levels
were normalized to total protein amount and expressed as ng neurotransmitter/mg protein.
DA and 5-HT turnover rates were also calculated.
2.9. Quantitative Real-Time RT-PCR
The transcription levels of mRNA encoding Ctr1, Dmt1, Mt1a, Mt2a, Mt3, Gfap, Nestin,
Dcx, NeuN, Th, and Gad67 were quantified using qPCR. The forward and reverse primers
for all selected target genes and reference gene were designed using Primer Express 3.0
software. The sequences for all primers are listed in Table 1. All primers were obtained
from Integrated DNA Technologies Ltd. (Coralville, IA, USA). Total RNA was isolated
from control, Cu-deficient and Cu-overload rat CP, SVZ, and OB tissues by using TRIzol
reagent following the manufacturer’s directions. An aliquot of RNA (1 µg) was reversetranscribed into cDNA using the BioRad iScript cDNA synthesis kit. The iTaq Universal
SYBR Green Supermix was used for qPCR analyses. The amplification was run in the CFX
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Connect Real-Time PCR Detection System with an initial 3 min denaturation at 95 ◦ C, the
amplification program was followed by 40 cycles of 30 s denaturation at 95 ◦ C, 10 s at 60 ◦ C
and 30 s extension at 72 ◦ C. A dissociation curve was used to verify that the majority of
fluorescence detected could be attributed to the labeling of specific PCR products, and to
verify the absence of primer dimers and sample contamination. Each qPCR reaction was
run in triplicate.
Table 1. The forward and reverse primer sequences of target genes.
Category
Reference Gene

Gene
Actb

Forward:
Reverse: 50 -CTCTCAGCTGTGGTGGTGAA-30

Ctr1

Forward: 50 -TCGGCCTCACACTCCCACGA-30
Reverse: 50 -CGAAGCAGACCCTCTCGGGC-30

Dmt1

Forward: 50 -TCGCAGGCGGCATCTTGGTC-30
Reverse: 50 -TACCGAGCGCCCACAGTCCA-30

Mt1a

Forward: 50 -GCCTTCTTGTCGCTTACACC-30
Reverse: 50 -AGGAGCAGCAGCTCTTCTTG-30

Mt2a

Forward: 50 -ACAGATGGATCCTGCTCCTG-30
Reverse: 50 -GAGAACCGGTCAGGGTTGTA-30

Mt3

Forward: 50 -CCCTGCAGGATGTGAGAAGT-30
Reverse: 50 -TTTGCTGTGCATGGGATTTA-30

Gfap

Forward: 50 -TAGCATAAGTGGAGAGGGAA-30
Reverse: 50 -GGATTCAGAGCCAAGTGTAA-30

Nestin

Forward: 50 -ATGAGGGGCAAATCTGGGAA-30
Reverse: 50 -CCAGGTGGCCTTCTGTAGAA-30

Dcx

Forward: 50 -ACTGAATGCTTAGGGGCCTT-30
Reverse: 50 -CTGACTTGCCACTCTCCTGA-30

NeuN

Forward: 50 -TTCCCACCACTCTCTTGTCC-30
Reverse: 50 -GCAGCCGCATAGACTCTACC-30

Th

Forward: 50 -CAGGGCTGCTGTCTTCCTAC-30
Reverse: 50 -GGGCTGTCCAGTACGTCAAT-30

Gad67

Forward: 50 -CACAAACTCAGCGGCATAGA-30
Reverse: 50 -CTGGAAGAGGTAGCCTGCAC-30

Cu Transporter

Cu Binding Proteins

Primer Sequence
50 -AGCCATGTACGTAGCCATCC-30

Neuronal Markers

Note: The PCR primer efficiencies for listed primers were between 90% and 97%.

The relative mRNA expression ratios between groups were calculated using the deltadelta cycle time formulation. After confirming that the reference gene was not changed,
the cycle time values of interested genes were normalized with that of the reference gene
in the same sample, and then the relative ratio between control and treatment groups
was calculated and expressed as relative increases by setting the control as 100%. The
amplification efficiencies of target genes and the internal reference were examined by
determining the variations of the cycle time with a series of control template dilutions.
Experimental conditions were optimized for annealing temperature, primer specificity, and
amplification efficiency.
2.10. Statistical Analysis
All data are presented as mean ± SEM. Statistical analyses of the differences among
control, CuD, and CuO groups were carried out by one-way ANOVA with a Tukey’s post
hoc test. Since behavioral data were not normally distributed, this set of data was analyzed
using the Mann–Whiney U-test (difference between two groups) or the Kruskal–Wallis
nonparametric ANOVA (differences among three groups) followed by a Dunn’s test. All
the statistical analyses were conducted using GraphPad Prism 6 software (GraphPad,
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control, CuD, and CuO groups were carried out by one-way ANOVA with a Tukey’s post
hoc test. Since behavioral data were not normally distributed, this set of data was analyzed
using the Mann–Whiney U-test (difference between two groups) or the Kruskal–Wallis
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nonparametric ANOVA (differences among three groups) followed by a Dunn’s test. All
the statistical analyses were conducted using GraphPad Prism 6 software (GraphPad, San
Diego, CA, USA). The differences between two means were considered significant at p ≤
San
0.05.Diego, CA, USA). The differences between two means were considered significant at
p ≤ 0.05.
3. Results
3. Results
3.1. Systemic Cu Dyshomeostasis and Impaired Olfactory Function Following CuD or CuO
3.1. Systemic Cu Dyshomeostasis and Impaired Olfactory Function Following CuD or
Treatment
CuO Treatment
CuD and CuO treatments did not cause significant changes in rat body weight comCuD and CuO treatments did not cause significant changes in rat body weight compared
to controls
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(data presented
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in Figure
Figure S1).
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controls,
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Cu
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oltory function.
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2).
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aprats (about 60 seconds) (p < 0.01, Figure 2). In other words, CuD- or CuO- animals took
proximately
4
times
longer
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controls
to
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the
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suggesting
that
both
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approximately 4 times longer than controls to find the food pellet, suggesting
Cu
conditions are
are capable
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sensory function.
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Figure 2. Buried
Buriedpellet
pellettest
testtotodetermine
determineolfactory
olfactoryfunction.
function.
Rats
were
treated
with
CuD
or CuO
Rats
were
treated
with
CuD
or CuO
as
described
in Figure
1A.1A.
Tests
were
performed
at the
CuD
or CuO
treatment
following
as
described
in Figure
Tests
were
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at end
the of
end
of CuD
or CuO
treatment
following
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training and
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diet restriction.
restriction. Data
**:**:
p <p 0.01,
as as
three-day
Data represents
represents mean
mean ±±SEM,
SEM,nn==14/group.
14/group.
< 0.01,
compared to the control group, using Kruskal-Wallis nonparametric ANOVA analysis. Ct: control;
CuD: Cu deficiency; CuO: Cu overload.

3.2. Altered Brain Regional Cu Levels Following CuD or CuO Treatment
Previous studies from our laboratory have determined high Cu accumulation within
the adult rat SVZ and OB [23,61], suggesting a crucial role of Cu in regulating adult
neurogenesis, particularly in the SVZ-RMS-OB axis. As the first step to understand Cumediated mechanisms of olfactory dysfunction, we measured Cu levels in the SVZ-RMS-OB
regions (i.e., OB, RMS, SVZ and choroid plexus), to compare to other brain regions (i.e.,
striatum (STR), hippocampus (HP), frontal cortex (FC), and cerebellum (CB)), in CuO, CuD,
and control rats. Our data revealed that the 2-week CuD treatment markedly reduced Cu
levels in the OB, RMS horizontal arm (olfactory tract), and SVZ (Figure 3A). The 2-week
CuO treatment only increased the Cu levels in the SVZ, but had no effect on Cu levels in
OB and RMS (p < 0.001, Figure 3A).
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ated mechanisms of olfactory dysfunction, we measured Cu levels in the SVZ-RMS-OB
regions (i.e., OB, RMS, SVZ and choroid plexus), to compare to other brain regions (i.e.,
striatum (STR), hippocampus (HP), frontal cortex (FC), and cerebellum (CB)), in CuO,
CuD, and control rats. Our data revealed that the 2-week CuD treatment markedly reduced Cu levels in the OB, RMS horizontal arm (olfactory tract), and SVZ (Figure 3A).
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2-week CuO treatment only increased the Cu levels in the SVZ, but had no effect on Cu
levels in OB and RMS (p < 0.001, Figure 3A).

Figure 3.
3. Brain
Cu concentrations
in selected brain
regions CuD
following
CuD
or CuO treatment.
Brain
tissues
were and
dissected
and
Figure
regional Cu concentrations
following
or CuO
treatment.
Brain tissues
were
dissected
analyzed
analyzed
for
Cu
by
AAS.
Data
represents
mean
±
SEM,
n
=
6–7/group.
*:
p
<
0.05,
**:
p
<
0.01,
***
p
<
0.001,
as
compared
to
for Cu by AAS. Data represents mean ± SEM, n = 6–7/group. *: p < 0.05, **: p < 0.01, ***: p < 0.001, as compared to the
the
correspondent
Ct
group,
using
one-way
ANOVA
analysis.
Ct:
control;
CuD:
Cu
deficiency;
CuO:
Cu
overload;
CSF:
correspondent Ct group, using one-way ANOVA analysis. (A). Cu levels in the SVZ-RMS-OB axis and choroid plexus.
cerebrospinal fluid; OB: olfactory bulb; RMS: rostral migratory stream; SVZ: subventricular zone; CP: choroid plexus; STR:
(B). Cu levels in selected brain regions. Ct: control; CuD: Cu deficiency; CuO: Cu overload; CSF: cerebrospinal fluid;
striatum; HP: hippocampus; FC: frontal cortex; CB: cerebellum.
OB: olfactory bulb; RMS: rostral migratory stream; SVZ: subventricular zone; CP: choroid plexus; STR: striatum; HP:
hippocampus; FC: frontal cortex; CB: cerebellum.

Interestingly, a significant increase of Cu was found in the choroid plexus of CuDtreated
rats (p < 0.05),
which was
opposite
to the
observed
in of
theCuDOB,
Interestingly,
a significant
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wasgeneral
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and
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(Figure
3A).
As
a
barrier
between
the
blood
and
CSF,
it
is
possible
that
the
treated rats (p < 0.05), which was opposite to the general decreases observed in the OB,
blood-CSF
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of
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a
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in
systemic
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in
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RMS, and SVZ (Figure 3A). As a barrier between the blood and CSF, it is possible that the
may
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the loss plexus,
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the CSF to
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CSF
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Cu in CuD,
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Cu
levels
in
other
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may retain or slow down the loss of Cu from the CSF to maintain CSF Cu homeostasis.
such Altered
as in thesystemic
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and CB. Our
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thatlevels
the 2-week
treatment
CuFC,
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could
also
affect Cu
in otherCuD
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regions
caused
a
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Cu
only
in
STR
(p
<
0.05
compared
with
controls,
Figure
such as in the STR, HP, FC, and CB. Our data showed that the 2-week CuD treatment caused
3B),
but
not
in
other
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brain
regions.
In
contrast,
the
2-week
CuO
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caused
a significant reduction of Cu only in STR (p < 0.05 compared with controls, Figure 3B), but
significant
increases
in all four
brain
compared
to caused
controlssignificant
(p < 0.01,
not in otherCu
tested
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contrast,
theregions
2-week as
CuO
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Figure
3B). Itinappeared
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with
olfactory(pfunction
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regions associated
as compared
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< 0.01, Figure
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though
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function
andCuD
adulttreatment
neurogenesis
otherOB,
brain
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ap(i.e.,
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SVZ)Conversely,
tended to beother
morebrain
sensitive
to tested
the CuD
treatment
other
brain
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to
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more
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to
the
CuO
treatment
than
the
SVZ-RMS-OB
regions.
regions. Conversely, other brain regions tested (i.e., STR, HP, FC and CB) appeared to be
more sensitive to the CuO treatment than the SVZ-RMS-OB regions.
3.3. Altered Expressions of Neuronal Markers Following Systemic CuD or CuO Treatment
3.3. Altered
Expressions
of Neuronal
Following
CuD residing
or CuO Treatment
The adult
OB circuits
consistMarkers
of diverse
typesSystemic
of neurons
in each layer;

Thethem,
adulttwo
OB neuronal
circuits consist
types
of neurons
residing inneurons
each layer;
among
among
types of diverse
particular
interest
are GABAergic
expressing
them, twoacid
neuronal
types of particular
interestisoform
are GABAergic
expressing glutamic
glutamic
decarboxylase
protein 67-kDa
(GAD67)neurons
and dopaminergic
neurons
acid decarboxylase
67-kDa(TH)
isoform
anddata
dopaminergic
neurons
expressing
expressing
tyrosineprotein
hydroxylase
[62].(GAD67)
Our qPCR
showed that
the expression
of
tyrosine hydroxylase (TH) [62]. Our qPCR data showed that the expression of Gad67 mRNA
in the OB was significantly upregulated by 40% and downregulated by 36% after the CuD
and CuO treatment, respectively, when compared with controls (p < 0.01, Figure 4A).
Treatments with either CuD or CuO, however, significantly reduced mRNA expression of
Th in the OB, about 24% and 31% as compared to controls, respectively (p < 0.05, Figure 4A).
Hence, the disrupted Cu homeostasis appeared to affect the neuron populations in the
adult OB circuits, which could influence the secretion of neurotransmitters and alter normal
olfactory function.
New neurons in the adult OB are originated from the SVZ, where adult neural stem
cells (i.e., Type-B cells expressing cellular marker Gfap) proliferate to generate rapidly
dividing transient amplifying cells (i.e., Type-C cells expressing marker Nestin), which give
rise to neuroblast cells (i.e., Type-A cells expressing Dcx); these neuroblasts arrive the OB
via the RMS and further differentiate into mature neurons (expressing marker NeuN) in
OB [28,62–65]. To distinguish and identify the phenotypes of interested neural stem cells,
neuroblasts, and neurons in the OB as influenced by disrupted adult neurogenesis in the
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Gad67 mRNA in the OB was significantly upregulated by 40% and downregulated by 36%
after the CuD and CuO treatment, respectively, when compared with controls (p < 0.01,
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Figure 4A). Treatments with either CuD or CuO, however, significantly reduced mRNA
expression of Th in the OB, about 24% and 31% as compared to controls, respectively (p <
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4B).and
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of <
these
cells inthat
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and OB.
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proliferation
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the
abundant
Type
stemwas
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Our data showed that the mRNA expression of Nestin GFAP(+)
and Dcx in
theBSVZ
the
SVZ.
nificantly upregulated by 2.1- and 1.8-fold, respectively, following 2-week CuD treatment
In the OB
vivo
Cu deficient
and overload
resulted
in a
as compared
to tissue,
controlsboth
(p <in
0.01,
Figure
4B); however,
the CuOtreatments
treatment did
not affect
markedexpression
inhibition in
mRNA
expression
of neuroblast
marker
by 20% and
45%,
mRNA
of the
Nestin
and Dcx
in the SVZ
(Figure 4B).
TheseDcx
alterations
in Nestin
respectively
(p
<
0.05,
Figure
4C).
Noticeably,
the
neuroblasts
that
were
upregulated
in
and Dcx suggest that the CuD condition stimulates the proliferation of Type-C transient
the SVZ (Figure 4A) did not seem to arrive or survive in the OB after CuD treatment
cells and Type-A neuroblasts, while these stem cells appear to tolerate CuO.
(Figure 4C). In comparison to control rats, the NeuN mRNA expression level in the OB
Interestingly, both CuD and CuO treatments significantly suppressed the mRNA exafter CuD treatment was significantly increased by 33%, and yet a significant reduction of
pression of Gfap in the SVZ, a marker for Type-B progenitor cells, as compared to controls
NeuN mRNA expression by 48% was observed in the OB of CuO-treated animals (p < 0.05,
(p < 0.01, Figure 4B). The results indicate that a balanced Cu homeostasis is essential to
Figure 4C). These findings imply that an altered systemic Cu status may cause aberrant
regulation of multiple processes contributing to disruption of proliferation, migration, and
possibly differentiation of NeuN(+) neurons from the SVZ-originated DCX(+) neuroblasts
in the OB.
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4C). In comparison to control rats, the NeuN mRNA expression level in the OB after CuD
treatment was significantly increased by 33%, and yet a significant reduction of NeuN
mRNA expression by 48% was observed in the OB of CuO-treated animals (p < 0.05, Figure
4C). These findings imply that an altered systemic Cu status may cause aberrant regulation of multiple processes contributing to disruption of proliferation, migration, and11posof 23
sibly differentiation of NeuN(+) neurons from the SVZ-originated DCX(+) neuroblasts in
the OB.
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By counting BrdU(+) proliferating cells in SVZ, our results showed that CuD and CuO
had the opposite effect by promoting and reducing the proliferation of NSPCs, respectively
(p < 0.01, Figure 5B). Thus, this evidence supports the view that Cu acts on a yet-to-beidentified regulatory mechanism by controlling adult neurogenesis in the SVZ, ultimately
affecting olfactory function.
3.5. Neurochemical Imbalance Following Systemic CuD or CuO Treatment
Neuronal active chemicals such as GABA, glutamate, and catecholamines are vital in
regulating olfactory function [66,67]. To investigate the influence of systemic Cu dyshomeostasis on the neurochemical balance of specific brain regions, a well-established HPLC
method was used to determine levels of GABA, glutamate, and monoamines (i.e., DA,
DOPAC, NE, 5-HT, 5-HIAA, and HVA) in the SVZ and OB in comparison to the striatum
and hippocampus, following the 2-week CuD or CuO treatments. GABA levels of the
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Neuronal active chemicals such as GABA, glutamate, and catecholamines are vital in
regulating olfactory function [66,67]. To investigate the influence of systemic Cu dyshomeostasis on the neurochemical balance of specific brain regions, a well-established HPLC
12 of 23
method was used to determine levels of GABA, glutamate, and monoamines (i.e.,
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nitude higher than those in the SVZ and striatum, which differed from the opposite magpattern observed in DA and DOPAC (Figure 7A vs. Figure 7C). Similar to the pattern in
nitude pattern observed in DA and DOPAC (Figure 7A vs. 7C). Similar to the pattern in
DOPAC (Figure 7B), the levels of HVA, a major catecholamine metabolite, were signifiDOPAC (Figure 7B), the levels of HVA, a major catecholamine metabolite, were significantly reduced in all tested brain regions following either CuD or CuO treatment, except
cantly reduced in all tested brain regions following either CuD or CuO treatment, except
for the CuO-treated hippocampus, as compared to controls (p < 0.05, Figure 7D). These
for the CuO-treated hippocampus, as compared to controls (p < 0.05, Figure 7D). These
findings indicate that systemic Cu dyshomeostasis disturbs DA pathways by interrupting
findings indicate that systemic Cu dyshomeostasis disturbs DA pathways by interrupting
DOPAC balance.
DOPAC balance.
5-HT status was also quantified in the selected brain regions. Following CuD or CuO
treatment, a significant increase in 5-HT was observed in the CuO-treated SVZ (p < 0.05,
Figure 7E). However, both treatments resulted in a marked reduction in striatum 5-HT
levels, while CuO treatment reduced OB 5-HT levels (p < 0.05, Figure 7E). The levels of
5-HIAA, a major metabolite of 5-HT, in the SVZ, OB and striatum were also significantly
reduced, as compared to controls, following both CuD and CuO treatments (p < 0.05,
Figure 7F). Noticeably, only in the OB were the turnover rates of 5-HT significantly slower
than those of the control OB in both CuD and CuO treated animals (p < 0.05, Figure 7G).
Taken together, these findings imply that the systemic Cu dyshomeostasis disrupts 5-HT
balance and its metabolism in the SVZ-OB axis of the rat brain.
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levels, while CuO treatment reduced OB 5-HT levels (p < 0.05, Figure 7E). The levels of 5HIAA, a major metabolite of 5-HT, in the SVZ, OB and striatum were also significantly
reduced, as compared to controls, following both CuD and CuO treatments (p < 0.05, Figure 7F). Noticeably, only in the OB were the turnover rates of 5-HT significantly slower
than those of the control OB in both CuD and CuO treated animals (p < 0.05, Figure 7G).
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Taken together, these findings imply that the systemic Cu dyshomeostasis disrupts 5-HT
balance and its metabolism in the SVZ-OB axis of the rat brain.
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The mRNA expression level of metallothionein proteins (MT1a, MT2a and MT3) in
the control OB were 12-, 28-, and 26-times higher than the expression level detected in
the control SVZ, respectively (p < 0.001, Figure 8B). Such enhanced levels indicated that
the OB could accumulate higher a level of Cu ions than the SVZ. Among those three
metallothionein genes in both control SVZ and OB tissues, Mt2a had the highest mRNA
expression, followed by Mt3 and Mt1a (Figure 8B), implying that MT2a and MT3 serve as
the key Cu storage protein in both tissues.
The 2-week CuD and CuO treatments significantly downregulated and upregulated
Ctr1 mRNA expressions by 42% and 83% in the choroid plexus, respectively, as compared
to controls (p < 0.01, Figure 9A). In contrast to the transcriptional changes of Ctr1, the
expression of Dmt1 mRNA in the choroid plexus was markedly upregulated and downregulated after CuD- and CuO treatments, respectively (p < 0.01, Figure 9B). Specifically
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The 2-week CuD treatment significantly upregulated the mRNA expression of Mt1a
and Mt3 in the SVZ by 2.1 and 2.6 folds respectively, as compared to the control SVZ
(p < 0.001, Figure 9C,E). However, Mt2a mRNA expression in the SVZ was significantly
downregulated by both CuD and CuO treatments (p < 0.05, Figure 9D). In the OB, CuD
treatment significantly induced the mRNA expression of Mt1a and Mt2a by 32% and 28%,
respectively, without affecting the expression of Mt3, while the CuO treatment resulted
in significant downregulation of all three genes by 53% in Mt1a, 44% in Mt2a, and 42%
in Mt3, as compared to those of controls (p < 0.05, Figure 9C–E). The downregulation of

Biomolecules 2021, 11, 1315

16 of 23

Ctr1, Dmt1, Mt1a, Mt2a, and Mt3 in the OB of CuO animals seems likely to indicate that
this is a mechanism to regulate and maintain local Cu homeostasis in the OB under the
systemic Cu overload condition, which is in agreement with AAS data where no significant
Cu accumulation was observed in the OB of CuO rats (Figure 3A).
4. Discussion
The question of whether distorted Cu homeostasis affects olfactory function has long
been unanswered. The current in vivo study provides first-hand evidence that systemic
Cu dyshomeostasis, specifically Cu deficiency or Cu overload, likely impairs olfactory
function by diminishing the animal’s natural sensation of smelling and food-finding. This
impaired olfactory function under Cu dyshomeostasis is believed to be due, at least in part,
to the disruption of Cu-mediated regulation of adult neurogenesis in the SVZ-RMS-OB axis.
This conclusion is supported by several lines of observations. First, both CuD and CuO
result in treatment-dependent reduction or elevation of Cu levels in local brain regions
critical to olfactory function. Second, the locally altered Cu levels in the OB, RMS and SVZ
apparently disrupt populations of GABA and DA neurons in OB, along with altering the
expression of cellular markers for proliferation, migration, and differentiation of neural
stem and progenitor cells in the SVZ-RMS-OB axis. Third, CuD and CuO treatments cause
abnormal changes in neuroactive amino acids and monoamines in critical brain areas that
regulate olfactory function. Finally, in vivo Cu dyshomeostasis clearly impairs mechanisms
whereby Cu in the central milieus is regulated by transporters across brain barriers and
storage proteins in local tissues. These observations support an essential role of Cu in adult
neurogenesis and pertinent normal olfactory function.
Olfactory impairments, such as deficits in odor identification, detection, and discrimination, are found in patients with PD and AD [35,36,68,69]. Particularly with regards to
PD, the olfactory dysfunction is one of the initial symptoms occurring years before motor
symptoms and cognitive deficiency become evident. Thus, olfactory dysfunction has been
suggested as a clinical indicator of the early stages of PD and also as an indicator of disease
progression aiding in diagnosis [70]. The role of Cu in regulating olfactory function in
healthy and disease conditions remains largely unknown. However, a few studies utilizing
zebrafish models have provided the initial evidence to support Cu exposure and ensuing
impaired olfaction. Specifically, they demonstrate Cu-mediated loss of behaviors critical to
fish involving olfaction, such as predator avoidance, prey capture, mate selection, social
behavior and migration [71–73].
Works by Baldwin et al., [71] report a Cu-dose-dependent inhibition of olfactorymediated behaviors that are critical for the survival and migratory success of wild salmonids.
By using the electro-olfactography to measure the level of olfactory dysfunction in zebrafish
models, Dew et al. [74] reveal that exposure to a low, ecologically relevant Cu concentration
causes a significant inhibition of olfactory activities. Julliard et al. (1996) also observe
that olfactory deficits in zebrafish caused by Cu exposure can trigger aberrant olfactory
neurogenesis, affecting both mature and immature neurons; the authors conclude that
these responses are related to receptor-mediated cell death in the OB. Our observation of
diminished olfactory function following systemic Cu dyshomeostasis in rats is in a good
agreement with these previous reports from fish studies. Although little is known about
the precise location of Cu in the OB, previous studies have shown that the mammalian
OB has high concentrations of zinc (Zn) and Cu compared to other CNS regions [75,76].
Further, Zn is identified to exist primarily in olfactory sensory neuron terminals in the
glomerular layer and neuron terminals in the granule cell layer [77–79]. With the close
companionship that exists between Zn and Cu, Cu would likely concentrate within the
olfactory sensory neurons as well. In addition, in vitro studies have observed that Cu
influences the excitability of rat OB neurons by multiple mechanisms such as eliminating
GABA-mediated spontaneous inhibitory postsynaptic potential, blocking the spontaneous
glutamate-mediated excitatory synaptic activity, inhibiting sodium channels, and delayed
rectifier-type potassium channels, etc. [80–83].
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Several mechanisms may underscore Cu’s disruptive impact on olfactory function.
The altered Cu level in critical brain regions relevant to olfaction (i.e., OB, SVZ, RMS)
may cause alterations in adult neurogenesis in these areas affecting olfaction. This was
suggested based on increases in proliferating markers in the SVZ of CuD and inhibition
of these markers in the SVZ of CuO. It is possible that the loss of olfactory neurons may
trigger adult neurogenesis in the SVZ-RMS-OB system by increasing the proliferation of
olfactory NSPCs to replace the damaged sensory neurons in the OB. A zebrafish study
demonstrates that Cu exposure can cause olfactory dysfunction and induce abnormal
neurogenesis [4]. Moreover, a recent study by Ma et al. [84] demonstrates that transgenic
zebrafish with diminished olfactory sensory neurons display an increased BrdU labeling
after Cu exposure. Their further olfactory behavioral analyses reveal that the initial loss
comes with a later restoration of olfactory neurons, which likely compensates for Cuinduced olfactory dysfunction. Our current study extended the research focus beyond the
OB by examining responses throughout the entire SVZ-RMS-OB axis. Our data clearly
establishes that the impact of systemic Cu disorder is not solely limited to the OB, but
rather adversely affects processes of neurogenesis from its origin in the SVZ and along the
SVZ-RMS-OB axis.
Noticeably, the Cu concentration in the SVZ is about 20–30 times higher than other
brain regions, CSF, and plasma [19,23]. In our previous publications, we hypothesized
that such a high Cu status in the SVZ may be necessary to maintain adult neurogenesis
in this proliferative niche [19,24,61]. Although the amount of Cu necessary to regulate
proliferation, differentiation, and migration of NSPCs in the SVZ-RMS-OB axis remains
unknown, our current data appear to suggest that a disrupted Cu homeostasis impacts
adult neurogenesis. Specifically, a reduced Cu status in the SVZ, as a result of CuD, may
directly activate adult neurogenesis in the SVZ. This postulation was supported by the
observation that Nestin(+) Type-C transit-amplifying cells and DCX(+) Type-A migratory
neuroblasts were elevated following CuD treatment. In contrast, under high Cu conditions
such as in the CuO animals, proliferation of GFAP(+) Type-C astrocytic stem cells and
differentiation of NSPCs to NeuN(+) immature neurons were inhibited in the OB, pointing
to an impaired adult neurogenesis. These observations prompt a new hypothesis that Cu
in the SVZ functions as a biological “switch” that regulates adult neurogenesis. Specifically,
adult neurogenesis is activated when Cu levels are low and inhibited when Cu levels are
high. The molecular and cellular mechanisms by which Cu acts on its putative ligands
thus warrant further investigation.
Our data determined an increased DCX expression in the SVZ and yet a reduced
DCX expression in the OB of CuD rats. This could be due to unsuccessful arrival and/or
reduced survival of SVZ-originated DCX(+) neuroblasts in the OB following CuD treatment. However, the possibility that some of the SVZ-originated neuroblasts may have
differentiated into mature neurons at the time of experimentation cannot be ruled out.
In fact, the latter hypothesis is partly supported by the observation of increased NeuN
expression in the OB of the same CuD animals. Nonetheless, our observations support the
disrupted proliferation, migration, and neuronal cell populations in the adult SVZ-RMS-OB
system following disruption of Cu homeostasis.
Abnormal changes in neuroactive amino acids and monoamines in brain regions
critical to olfaction may underlie Cu dyshomeostasis-associated olfactory dysfunction.
Especially compelling in the CuO condition is the large increase in olfactory GABA and
decreases in monoamine neurotransmitters/metabolites which could impact olfactory
dysfunction. Reports in literature have suggested that Cu is an essential cofactor for at least
twelve mammalian enzymes including dopamine beta-mono-oxygenase and actively participates in the synthesis of catecholamines, neuropeptide, and tyrosinase [47,85]. Reduced
dopamine has been associated with dietary Cu deficiency in humans [86]. In addition, Cu
ions have been found in synapses where they are released into the synaptic cleft, bind
to neurotransmitters, and regulate activities of postsynaptic receptors, such as GABA
receptors [6,87,88]. Thus, it seems likely the neurochemical imbalance observed in the SVZ,
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striatum, and hippocampus in the current study may be a direct result of altered Cu levels
in these brain regions with ensuing disruptions in yet-to-be-defined Cu-sensitive pathways.
These alterations may, in turn, underscore the motor and/or neurobehavioral dysfunction
following systemic Cu dyshomeostasis.
Overall, Cu dyshomeostasis produces complex changes in neurotransmission that
need to be further investigated. Given the effects on neurotransmitter metabolites and
turnover observed in many brain regions, it becomes critical to examine whether Cu
dyshomeostasis directly affects enzymes involved in neurotransmitter metabolism and
also whether neurotransmitter release is modulated. Here, our surprising finding is that
both Cu overload and deficiency seemed to produce similar alterations in monoamine
neurotransmitters. Thus, it may be that a metal imbalance (in this case Cu) drives changes
in neurotransmitter release/metabolism rather than their absolute levels. Specifically, increased or decreased levels of Cu do not produce differential effects but cause similar effects
in regards to neurotransmitters. Data indicates an optimum threshold requirement that
could be affecting two processes simultaneously: neurotransmitter release and metabolism.
Systemic Cu dyshomeostasis was determined to influence Cu levels in distinct local
brain regions. Under normal physiological conditions, Cu is strictly regulated by a complex
regulatory system involving membrane-bound Cu transporters, intracellular Cu chaperons, Cu-binding storage proteins, and cuproenzymes [39]. Cu in the blood circulation is
transported into the brain and CSF via the blood-brain barrier and blood-CSF barrier in the
choroid plexus, respectively [39,41,56]. As a barrier between the blood and CSF, the choroid
plexus regulates the CSF Cu homeostasis. A significant increase in Cu was observed in
the plexus tissue of CuD-treated rats, while Cu levels in the OB, RMS, and SVZ decreased.
This observation possibly indicates that the choroid plexus may respond to systemic CuD
by retaining or reducing the loss of Cu to maintain Cu homeostasis in the CSF.
In the brain, Cu is unevenly distributed [13,89–93], varies among species [94–96], and
changes during development and in neurodegenerative conditions [97–100]. Markedly
higher levels of Cu are found in the substantia nigra, locus coeruleus, and hippocampus [91,101–103]. The current study shows a higher expression of Cu transport proteins in
the choroid plexus, which regulates Cu transport between the blood and CSF, than other
tested brain regions and a comparatively lower expression of Cu storage proteins. These
observations confirm similar distribution patterns of Cu regulatory proteins in previous
reports [19,104,105]. An increase in a major Cu storage protein MT3 in SVZ and MT2 in OB
after CuD treatment may explain the higher Cu levels in these tissues, while a decreased
MT2 and MT3 in the SVZ and OB following CuO treatment may underscore lower Cu
levels in the SVZ and OB.
The current study has several limitations. First, determination of neuronal markers
such as Dcx (for Type A migratory neuroblasts), Nestin (for Type C transit-amplifying
cells), GFAP (for Type B astrocytic stem cells), and NeuN (for mature neurons) is a valid
approach to reflect the status of adult neurogenesis in the SVZ-RMS-OB axis. Yet, a more
direct approach pertains to counting specific cell types double-labeled with BrdU. Second,
the changes of a group of Cu transport and storage proteins were assayed by qPCR. In our
future studies, it is desirable to conduct confocal experiments to verify alterations in the
expression of these Cu regulatory proteins.
Finally, the phospholipids, mainly phosphatidylcholine and phosphatidylethanolamine,
account for 81% (by weight) of the total lipid in rat olfactory mucosa, playing an indispensable role in maintaining the normal olfaction [106]. Recent data have suggested that chronic
CuO in rats causes brain redox imbalance by generating free radicals via phospholipid
peroxidation [107]. The evidence to suggest an interaction between Cu dyshomeostasis
and phospholipid disruption in OB remains elusive; however, such a hypothesis along
with changed endocannabinoid levels deserves further exploration.
In summary, our results from the animal models of Cu deficiency and Cu overload
demonstrate systemic Cu dyshomeostasis can cause olfactory dysfunction. Further, mechanistic investigation suggests altered Cu status in local brain areas critical to olfaction may
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disrupt adult neurogenesis in the SVZ-RMS-OB axis, which supplies newly proliferated
and differentiated neurons to the OB. These observations provide the first evidence to
support a critical role of Cu in adult neurogenesis and in regulating olfactory function.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/biom11091315/s1, Figure S1: Record of rat body weights during the course of Cu treatment.
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